{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:21:43Z","timestamp":1772155303661,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["University of Oxford received a Special Project Grant from 2003 to 2008 (SP\/03\/002)"],"award-info":[{"award-number":["University of Oxford received a Special Project Grant from 2003 to 2008 (SP\/03\/002)"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["followed by two renewals of the grant in 2009-2013 (SP\/08\/010\/259)"],"award-info":[{"award-number":["followed by two renewals of the grant in 2009-2013 (SP\/08\/010\/259)"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["2015-2019 (SP\/14\/3\/31114)"],"award-info":[{"award-number":["2015-2019 (SP\/14\/3\/31114)"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer and Solvay Pharmaceuticals","award":["the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) at the University of Oxford received study drug"],"award-info":[{"award-number":["the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) at the University of Oxford received study drug"]}]},{"name":"Bayer and Solvay Pharmaceuticals","award":["funding for drug packaging"],"award-info":[{"award-number":["funding for drug packaging"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["the Clinical Trial Service Unit"],"award-info":[{"award-number":["the Clinical Trial Service Unit"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["Epidemiological Studies Unit (CTSU) received funding the UK Medical Research Council"],"award-info":[{"award-number":["Epidemiological Studies Unit (CTSU) received funding the UK Medical Research Council"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["Some study staff at the Clinical Trial Service Unit"],"award-info":[{"award-number":["Some study staff at the Clinical Trial Service Unit"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["Epidemiological Studies Unit (CTSU) at the University of Oxford supported by this funder."],"award-info":[{"award-number":["Epidemiological Studies Unit (CTSU) at the University of Oxford supported by this funder."]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023699","name":"Health Data Research UK","doi-asserted-by":"publisher","award":["the Clinical Trial Service Unit"],"award-info":[{"award-number":["the Clinical Trial Service Unit"]}],"id":[{"id":"10.13039\/501100023699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023699","name":"Health Data Research UK","doi-asserted-by":"publisher","award":["Epidemiological Studies Unit (CTSU) at the University of Oxford is the recipient"],"award-info":[{"award-number":["Epidemiological Studies Unit (CTSU) at the University of Oxford is the recipient"]}],"id":[{"id":"10.13039\/501100023699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>ASCEND assessed the effects of randomisation to aspirin versus placebo and, separately omega-3 fatty acid (FA) supplementation versus placebo on vascular events in 15480 adults with diabetes using mail-based remote methods. This analysis investigates factors associated with adherence to the allocated treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adherence was estimated from the 6-monthly follow-up forms and the supply of study treatment packs. A binary adherence variable, full versus less than full adherence during the period at risk of a serious vascular event (SVE), was investigated using logistic regression. Potential predictors of adherence considered were sex, age at randomisation, Hospital Frailty Risk Score, ethnicity, Townsend index, smoking status, type of diabetes, predicted 5-year vascular risk, number of other medications reported at study entry and treatment allocation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven thousand, three hundred twelve (47.2%) participants were fully adherent to aspirin\/placebo and 8937 (57.7%) were fully adherent to omega-3 FA\/placebo while at risk of a SVE. Women were less likely to be fully adherent than men (aspirin randomisation: 2509 [43.3%] vs. 4803 [49.6%]; OR, 0.73; 95% CI: 0.68 to 0.80;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001; omega-3 FA randomisation: 3035 [52.4%] vs. 5902 [61.0%]; OR, 0.67; 95% CI: 0.61 to 0.72;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and adherence decreased with increasing frailty (trend\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009&lt;\u20090.0001), smoking (\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009&lt;\u20090.0001), vascular risk score (\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009&lt;\u20090.0001) and deprivation (trend\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009=\u20090.0211,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0011).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We show this large, mail-based trial has comparable adherence with less streamlined trials in similar populations. In ASCEND, women and those with higher levels of frailty, smoking and vascular risk score had poorer adherence to trial medication. Trialists should consider strategies to improve adherence in these participant groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09551-4","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:52:56Z","timestamp":1772153576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with adherence to allocated treatment in the ASCEND trial: a mail-based randomised trial of aspirin and of omega-3 fatty acid supplementation in people with diabetes"],"prefix":"10.1186","volume":"27","author":[{"given":"Vichithranie W.","family":"Madurasinghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Mafham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"9551_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ahj.2017.12.006","volume":"198","author":"L Bowman","year":"2018","unstructured":"Bowman L, et al. ASCEND: a study of cardiovascular events iN diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. Am Heart J. 2018;198:135\u201344.","journal-title":"Am Heart J"},{"issue":"16","key":"9551_CR2","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529\u201339.","journal-title":"N Engl J Med"},{"issue":"1","key":"9551_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13063-016-1354-9","volume":"17","author":"T Aung","year":"2016","unstructured":"Aung T, et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: a study of cardiovascular events iN diabetes (ASCEND). Trials. 2016;17(1):286.","journal-title":"Trials"},{"issue":"16","key":"9551_CR4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540\u201350.","journal-title":"N Engl J Med"},{"issue":"10132","key":"9551_CR5","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","volume":"391","author":"T Gilbert","year":"2018","unstructured":"Gilbert T, et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391(10132):1775\u201382.","journal-title":"Lancet"},{"issue":"1","key":"9551_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/sim.1485","volume":"23","author":"M Plummer","year":"2004","unstructured":"Plummer M. Improved estimates of floating absolute risk. Stat Med. 2004;23(1):93\u2013104.","journal-title":"Stat Med"},{"issue":"7","key":"9551_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1161\/CIRCULATIONAHA.120.052339","volume":"143","author":"ES Lau","year":"2021","unstructured":"Lau ES, et al. Sex, permanent drug discontinuation, and study retention in clinical trials: insights from the TIMI trials. Circulation. 2021;143(7):685\u201395.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"9551_CR8","first-page":"200","volume":"18","author":"ML Edwards","year":"2017","unstructured":"Edwards ML, Landray M, Bowman L, Armitage J. Factors influencing recruitment in large randomised trials. Meeting abstracts from the 4th international clinical trials methodology conference (ICTMC) and the 38th annual meeting of the society for clinical trials: Liverpool, UK. 07\u201310 may 2017. Trials. 2017;18(Suppl 1):200.","journal-title":"Trials"},{"issue":"6","key":"9551_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10654-012-9702-x","volume":"27","author":"NR Cook","year":"2012","unstructured":"Cook NR, Cole SR, Buring JE. Aspirin in the primary prevention of cardiovascular disease in the Women\u2019s Health Study: effect of noncompliance. Eur J Epidemiol. 2012;27(6):431\u20138.","journal-title":"Eur J Epidemiol"},{"issue":"23","key":"9551_CR10","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1001\/archinte.1994.00420230032005","volume":"154","author":"RJ Glynn","year":"1994","unstructured":"Glynn RJ, et al. Adherence to aspirin in the prevention of myocardial infarction. The Physicians\u2019 Health Study. Arch Intern Med. 1994;154(23):2649\u201357.","journal-title":"Arch Intern Med"},{"issue":"4","key":"9551_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3200\/BMED.34.4.145-155","volume":"34","author":"R Brunner","year":"2009","unstructured":"Brunner R, et al. Predictors of adherence in the Women\u2019s Health Initiative Calcium and Vitamin D Trial. Behav Med. 2009;34(4):145\u201355.","journal-title":"Behav Med"},{"key":"9551_CR12","unstructured":"England, P.H., Health profile for England: 2017, P.H. England, Editor. 2017."},{"issue":"5","key":"9551_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s11606-020-06447-0","volume":"36","author":"ME Wilder","year":"2021","unstructured":"Wilder ME, et al. The impact of social determinants of health on medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2021;36(5):1359\u201370.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"9551_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41416-024-02765-w","volume":"131","author":"S Rae","year":"2024","unstructured":"Rae S, et al. Social determinants of health inequalities in early phase clinical trials in Northern England. Br J Cancer. 2024;131(4):685\u201391.","journal-title":"Br J Cancer"},{"issue":"5","key":"9551_CR15","first-page":"574","volume":"28","author":"M Lemstra","year":"2012","unstructured":"Lemstra M, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28(5):574\u201380.","journal-title":"Can J Cardiol"},{"issue":"3","key":"9551_CR16","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2666-7568(21)00004-0","volume":"2","author":"A Street","year":"2021","unstructured":"Street A, et al. The use of linked routine data to optimise calculation of the hospital frailty risk score on the basis of previous hospital admissions: a retrospective observational cohort study. Lancet Healthy Longev. 2021;2(3):e154\u201362.","journal-title":"Lancet Healthy Longev"},{"issue":"10","key":"9551_CR17","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2666-7568(23)00164-2","volume":"4","author":"ME Malik","year":"2023","unstructured":"Malik ME, et al. Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longev. 2023;4(10):e552\u201360.","journal-title":"Lancet Healthy Longev"},{"issue":"9","key":"9551_CR18","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","volume":"125","author":"SH Naderi","year":"2012","unstructured":"Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125(9):882-7.e1.","journal-title":"Am J Med"},{"key":"9551_CR19","doi-asserted-by":"publisher","first-page":"7786174","DOI":"10.1155\/2022\/7786174","volume":"2022","author":"P Vora","year":"2022","unstructured":"Vora P, et al. Long-term adherence and persistence to low-dose aspirin for the prevention of cardiovascular disease: a population-based cohort study. Int J Clin Pract. 2022;2022:7786174.","journal-title":"Int J Clin Pract"},{"key":"9551_CR20","doi-asserted-by":"crossref","unstructured":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet, 1998;351(9098):233\u201341.","DOI":"10.1016\/S0140-6736(97)11475-1"},{"issue":"10152","key":"9551_CR21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","volume":"392","author":"JM Gaziano","year":"2018","unstructured":"Gaziano JM, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036\u201346.","journal-title":"Lancet"},{"issue":"23","key":"9551_CR22","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2014.15690","volume":"312","author":"Y Ikeda","year":"2014","unstructured":"Ikeda Y, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312(23):2510\u201320.","journal-title":"JAMA"},{"issue":"18","key":"9551_CR23","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"H Ogawa","year":"2008","unstructured":"Ogawa H, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134\u201341.","journal-title":"JAMA"},{"issue":"9250","key":"9551_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","volume":"357","author":"G de Gaetano","year":"2001","unstructured":"de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. collaborative group of the primary prevention project. Lancet. 2001;357(9250):89\u201395.","journal-title":"Lancet"},{"issue":"6618","key":"9551_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","volume":"296","author":"R Peto","year":"1988","unstructured":"Peto R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296(6618):313\u20136.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"9551_CR26","doi-asserted-by":"crossref","unstructured":"Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med, 1989. 321(3): p. 129\u201335.","DOI":"10.1056\/NEJM198907203210301"},{"key":"9551_CR27","doi-asserted-by":"crossref","unstructured":"Guirguis-Blake JM, E.C., Perdue LA, Sarah IB, Caitlyn AS, Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: An Evidence Update for the U.S. Preventive Services Task Force [Internet]. 2022, Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Apr. (Evidence Synthesis, No. 211.).","DOI":"10.1001\/jama.2022.3337"},{"issue":"3","key":"9551_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.2018.20578","volume":"321","author":"SL Zheng","year":"2019","unstructured":"Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277\u201387.","journal-title":"JAMA"},{"key":"9551_CR29","doi-asserted-by":"crossref","unstructured":"Aung, T., et al., P2088Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12\u201324 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial. European Heart Journal, 2017. 38(suppl_1).","DOI":"10.1093\/eurheartj\/ehx502.P2088"},{"issue":"10","key":"9551_CR30","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/sim.4780101010","volume":"10","author":"JM Lang","year":"1991","unstructured":"Lang JM, et al. Estimating the effect of the run-in on the power of the physicians\u2019 health study. Stat Med. 1991;10(10):1585\u201393.","journal-title":"Stat Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09551-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:52:58Z","timestamp":1772153578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09551-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9551"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09551-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Multi-centre Research Ethics Committee (MREC) approval was obtained in 2003 (North West REC, ref 03\/8\/087) for the study protocol and, in particular, to use centrally held diabetes registers to identify potential participants. Regulatory approval was obtained from the Medicines and Healthcare Products Regulatory Agency (MHRA), and permission to obtain identifiable details of people with diabetes without their explicit consent (in order to invite them to participate in the trial) was obtained from the Patient Information Advisory Group (PIAG), constituted under Sect.\u00a0 60 of the NHS Act 2001 (subsequently the National Information Governance Board under Sect.\u00a0 251 of the National Health Service Act 2006, and more recently the Confidentiality Advisory Group). The coordinating centre ensured that the necessary Research Governance approvals were also in place for the invitations to be sent from general practices. All participants took part in ASCEND provided written informed consent. This work uses data provided by patients and collected by the NHS as part of their care and support. Linked healthcare data on admissions to hospital were provided by NHS England, the Secure Anonymised Information Linkage (SAIL) at University of Swansea and Public Health Scotland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}